Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 443.75% | 429.41% | -- | -111.68% | -111.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 443.75% | 429.41% | -- | -111.68% | -111.59% |
| Cost of Revenue | 138.96% | 21.78% | -52.38% | -80.52% | -86.61% |
| Gross Profit | 32.11% | 43.22% | 52.76% | 60.56% | 63.67% |
| SG&A Expenses | -13.02% | -10.96% | -10.66% | -27.43% | -39.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.56% | -37.96% | 5.37% | 21.37% | 40.05% |
| Operating Income | 72.58% | 37.97% | -5.37% | -21.42% | -40.16% |
| Income Before Tax | 77.72% | 38.94% | -11.85% | -30.51% | -53.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 77.72% | 38.94% | -11.85% | -30.51% | -53.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 77.72% | 38.94% | -11.85% | -30.51% | -53.04% |
| EBIT | 72.58% | 37.97% | -5.37% | -21.42% | -40.16% |
| EBITDA | 72.71% | 38.05% | -5.40% | -21.52% | -40.35% |
| EPS Basic | 80.15% | 46.03% | 5.07% | -16.74% | -43.30% |
| Normalized Basic EPS | 80.17% | 46.07% | 5.31% | -16.35% | -42.92% |
| EPS Diluted | 80.65% | 47.51% | 7.93% | -16.38% | -46.97% |
| Normalized Diluted EPS | 80.17% | 46.07% | 5.31% | -16.35% | -42.92% |
| Average Basic Shares Outstanding | 20.89% | 19.21% | 17.43% | 11.35% | 5.32% |
| Average Diluted Shares Outstanding | 20.89% | 19.21% | 17.43% | 11.35% | 5.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |